Valneva Announces the Cancellation of Ordinary Shares Held
Holy-Grasslayer (France), October 4, 2021 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccines company, today announces that the Management Board has decided, during a meeting today, to cancel all the ordinary shares held by the Company following upon termination of its liquidity contract with Oddo BHF on June 11, 2021 (that is to say., 4,025 ordinary shares in total, representing 0.004% of the share capital).
The Company’s share capital is now set at € 14,986,674.45, divided into 99,890,649 ordinary shares and 20,514 preference shares convertible into ordinary shares, with a par value of € 0.15 each (that is to say. 99,911,163 shares in total).
About Valneva SE
Valneva is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines against infectious diseases for which a significant medical need is not met. The Company takes a highly specialized and focused approach to vaccine development, then applies its in-depth understanding of vaccine science to develop prophylactic vaccines against these diseases. Valneva has leveraged its expertise and capabilities both to successfully commercialize two vaccines and to rapidly advance a wide range of vaccine candidates in and across the clinic, including candidates for Lyme disease, the virus. chikungunya and COVID-19.
|Media and investor contacts
VP Global Communications & European Investor Relations
M +33 (0) 6 4516 7099
Joshua Drumm, Ph.D.